Table 7.
Efficacy of vaccines in response to corona virus variant.
| Vaccine | Efficacy at preventing disease: D614G & B.1.1.7 | Efficacy at preventing infection: D614G &B.1.1.7 | preventing disease: B.1.351, P.1, B.1.617 | Efficacy at preventing infection: B.1.351, P.1, B.1.617 |
|---|---|---|---|---|
| Pfizer/BioNTech | 91% | 86% | 86% | 82% |
| Moderna | 94% | 89% | 89% | 85% |
| AstraZeneca | 74% | 52% | 35% | 31% |
| Johnson & Johnson (Janssen) | 72% | 72% | 64% | 57% |
| Sputnik-V | 92% | 81% | 59% | 52% |
| Novavax | 89% | 79% | 49% | 43% |
| CoronaVac | 50% | 44% | 32% | 28% |
| Sinopharm | 73% | 65% | 47% | 41% |
| Tianjin CanSino | 66% | 58% | 42% | 37% |
| Covaxin | 78% | 69% | 50% | 44% |
| Other mRNA vaccines | 91% | 86% | 86% | 82% |
| All other vaccines | 75% | 66% | 57% | 50% |